J&J’s consumer pharmaceuticals valued at $40bn ahead of IPO – Kommersant
Johnson & Johnson's (J&J) consumer medicines division, which is being spun off into a separate company, is valued at $40...
pharmaceutical division
Johnson & Johnson to spin off consumer pharma to Kenvue
Today, September 28, Johnson & Johnson Corporation (J&J) announcedthat the new company into which it will spin off its consumer...
